This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Colorectal screening if colonic adenomas

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Consensus guidelines have been developed by the British Society of Gastroenterology, the Association of Coloproctology of Great Britain and Ireland and Public Health England (1)

Key recommendations are that the high-risk criteria for future colorectal cancer (CRC) following polypectomy comprise EITHER:

  • 2 or more premalignant polyps including at least one advanced colorectal polyp (defined as a serrated polyp of at least 10mm in size or containing any grade of dysplasia, or an adenoma of at least 10mm in size or containing high-grade dysplasia);
  • OR
  • 5 or more premalignant polyps

 


Notes:

  • a study found that stool-based post-polypectomy surveillance strategies (microsimulation modelling using annual FIT-based surveillance with FOB-gold at a threshold ≥32 μg/g faeces) can be safe and cost-effective, with potential to reduce the number of colonoscopies by up to 41% (2)

Reference:

  1. BSG/ACPGBI/PHE (September 2019).Post-polypectomy and post-colorectal cancer resection surveillance guidelines.
  2. Carvalho B et al. Stool-Based Testing for Post-Polypectomy Colorectal Cancer Surveillance Safely Reduces Colonoscopies: The Molecular Stool Testing for Colorectal Cancer Surveillance Study. Gastroenterology. 2024 Aug 30:S0016-5085(24)05402-7.

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.